FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	5)		•										
1. Name and Address of Reporting Person * Andrews Robert E			2. Issuer Name and Ticker or Trading Symbol Akers Biosciences Inc [AKER]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
, ,	(Last) (First) (Middle) 215 4TH AVENUE		3. Date of Earliest Transaction (Month/Day/Year) 12/30/2015					Office	r (give title belo	ow)	Other (specify b	elow)		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ Form fil	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
		ΓS, NJ 0803												
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Beneficially Owned Following Reported Transaction(s)		6. Ownership Form:	Beneficial		
				(Month/Day/Year)	Code	V	Amou	(A) or nt (D)		(Instr. 3 a	nd 4)		` /	Ownership (Instr. 4)
Common	Stock		12/30/2015		A		48,12	5 A	\$ 0	48,125			D	
				Derivative Securit		cont the f	ained in distinction of the dist	n this f splays of, or B	form a a curi enefici		uired to res	spond unle	ss	1474 (9-02)
1. Title of	2	3. Transaction	1	e.g., puts, cans, w	5.					Title and	8 Price of	9. Number	of 10.	11. Nature
Derivative Security	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Y	Execution Da Year) any	te, if Transaction Code (Instr. 8)		and (Mo	6. Date Exercisable and Expiration Date (Month/Day/Year)		Ai Ui Se	mount of nderlying ecurities nstr. 3 and	ount of derlying surities str. 3 and Derivative (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A) (D)			Expirat Date	ion Ti	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Andrews Robert E						
215 4TH AVENUE	X					
HADDON HEIGHTS, NJ 08035						

Signatures

/s/ Robert E. Andrews	12/31/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Such shares were issued under Akers Biosciences, Inc.'s Amended and Restated 2013 Incentive Stock and Award Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.